SEMA3A Exon 9 Expression Is a Potential Prognostic Marker of Unfavorable Recurrence-Free Survival in Patients with Tongue Squamous Cell Carcinoma
- 1 April 2020
- journal article
- research article
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 39 (4) , 555-562
Abstract
This study tried to assess the prognostic value of semaphorin (SEMA) family genes in patients with tongue squamous cell carcinoma (TSCC) and the potential epigenetic alterations of the genes. The part of third-level TSCC data in The Cancer Genome Atlas-Head and Neck Squamous Cell Carcinoma (TCGA-HNSC) was extracted using the UCSC Xena browser for analysis. Among 20 SEMA genes examined, 7 were markedly upregulated, while 8 were substantially decreased in TSCC tissues compared with adjacent normal tissues. SEMA3A was the only gene with independent prognostic value in terms of recurrence-free survival (RFS) in multivariate analysis (hazard ratio [HR]: 1.697, 95% CI: 1.228–2.345, p = 0.001). Among the individual exons of SEMA3A, the exon 9 had a better prognostic value in terms of recurrence than total SEMA3A expression and its expression also independently predicted shorter RFS (HR: 2.193, 95% CI: 1.463–3.290, p < 0.001). The methylation levels of two CpG sites (cg06144675 and cg13988052) were moderately correlated with SEMA3A expression. Interestingly, cg06144675, which locates at the promoter region, showed a negative correlation with SEMA3A expression, whereas cg13988052, which is in the intron of SEMA3A gene body showed a positive correlation with SEMA3A expression. In conclusion, SEMA3A expression is aberrantly upregulated in TSCC tissues. Its exon 9 expression is a potentially valuable prognostic marker of unfavorable RFS in TSCC patients. Both promoter hypomethylation and gene body hypermethylation might contribute to the dysregulation.Keywords
This publication has 37 references indexed in Scilit:
- Location, Location, Location: Macrophage Positioning within Tumors Determines Pro- or Antitumor ActivityCancer Cell, 2013
- Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor ImmunityCancer Cell, 2013
- Improvement in survival of patients with oral cavity squamous cell carcinoma: An international collaborative studyCancer, 2013
- Expression of semaphorin 3A and neuropilin 1 with clinicopathological features and survival in human tongue cancerMedicina Oral Patología Oral y Cirugia Bucal, 2012
- Conserved role of intragenic DNA methylation in regulating alternative promotersNature, 2010
- Age as a determinant of outcomes for patients with oral cancerOral Oncology, 2009
- Identification and tissue-specific expression of a novel isoform of Semaphorin 3DBiochimica et Biophysica Acta (BBA) - General Subjects, 2009
- High-resolution analysis of 3p deletion in neuroblastoma and differential methylation of the SEMA3B tumor suppressor geneCancer Genetics and Cytogenetics, 2007
- Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A–mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenograftsMolecular Cancer Therapeutics, 2006
- Promoter characterization of Semaphorin SEMA3F, a tumor suppressor geneBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 2005